Nippon India Pharma Fund - Direct Plan - Growth Plan
Equity
Direct
Sector - Healthcare
NAV: ₹ 465.51 as on 24-04-2024
Fund Performance
6556 people have invested ₹ 2.7Cr in Nippon India Pharma Fund - Direct Plan - Growth Plan in the last three months
Mutual Fund Insights
Over the last 1 year, this fund has decreased expense ratio by 27.0% moving from 1.26 to 0.92.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.92% which is lower than the category average expense ratio of 1.42%.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 18.72% return, outperforming this fund by 2.23% per annum.
Over the last 6 months, this fund has experienced a 25.3% growth in AUM moving from 5.68K Cr to 7.12K Cr.
This fund with AUM at ₹7125.28Cr is among the largest funds in the sector - healthcare category.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 27.2% return, outperforming this fund by 3.73% per annum.
In the last 1 year, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 57.38% return, outperforming this fund by 6.84%.
INDmoney Rank of Nippon India Pharma Fund - Direct Plan - Growth Plan
Powered by IND quant engine
IND ranking is not available for this fund.
Pros
Among most bought funds within the category
Larger AUM within category
Beats FD returns for both 3Y & 5Y duration
Cons
No bad points found for this fund.
About the Nippon India Pharma Fund - Direct Plan - Growth Plan
Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.
Key Parameters
- Nippon India Pharma Fund - Direct Plan - Growth Plan has ₹7125 Cr worth of assets under management (AUM) as on Mar 2024 and is more than category average.
- The fund has an expense ratio 0.9.
Nippon India Pharma Fund - Direct Plan - Growth Plan Overview
 | 0.92% |
 Benchmark | S&P BSE Healthcare PR |
 | ₹7125 Cr |
 | 1 January, 2013 |
 | ₹5000/₹100 |
 Exit Load | 1% |
 | No Lock-in |
 TurnOver | 18.67% |
Nippon India Pharma Fund - Direct Plan - Growth Plan Distribution as on (31-Mar-24)
Size breakup
Large cap
41.4%
Mid cap
33.1%
Small cap
22.6%
Sector Allocation
Health
100%
Top Holdings of Nippon India Pharma Fund - Direct Plan - Growth Plan as on (31-Mar-24)
Equity Holdings31
Debt Holdings1
Nippon India Pharma Fund - Direct Plan - Growth Plan: Monthly Changes Updates
All changes are between Jan'24 and Mar'24
Fund Performance
- This fund’s returns stands at -0.14% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.47% as on Mar'24
- This fund outperformed Nifty 500 by 0.33% in Mar'24
AUM Change
- AUM of the fund stands at 7.1K Cr as of Mar'24
- AUM decreased by 6.4 Cr between Mar'24 and Feb'24
Fund Portfolio Changes
Gainers & Losers in Nippon India Pharma Fund - Direct Plan - Growth Plan portfolio Returns for the month of Mar
Top Growth Drivers | 1M Return |
|---|---|
 J B Chemicals & Pharmaceuticals Ltd | 16% |
Peer Analysis
Nippon India Pharma Fund - Direct Plan - Growth Plan Fund Manager
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 1 April 2005
Top funds managed
Kinjal Desai
Fund Manager of Nippon India Pharma Fund - Direct Plan - Growth Plan, since 25 May 2018
Top funds managed
Nippon India Pharma Fund - Direct Plan - Growth Plan Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 18.22% since inception which is less than its category average return of 20.13%
Fund Allocations
This fund has an allocation of 97.16% in Equity, 0% in Debt and 2.84% in Cash related instruments
AUM size ₹7125 Cr
This fund has AUM of ₹7125 Cr which is more than its category average of ₹ 1652 Cr
Expense Ratio 0.92%
This fund has an expense ratio of 0.92% which is less than its category average expense ratio of 1.45%
Frequently Asked Questions
The current NAV of Nippon India Pharma Fund - Direct Plan - Growth Plan is ₹465.51 as on 24-Apr-2024.
Existing (Absolute + CAGR) as on 24-Apr-2024.
Nippon India Pharma Fund - Direct Plan - Growth Plan | Absolute Returns | CAGR Returns |
1 Month Returns | -0.83% | -0.83% |
6 Month Returns | 23.33% | 23.33% |
1 Year Returns | 50.54% | 50.54% |
3 Years Returns | 58.05% | 16.48% |
5 Years Returns | 186.92% | 23.47% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.92% as on March 2024
₹7125 Cr as on March 2024
Sun Pharmaceuticals Industries Ltd(14.91%), Lupin Ltd(8.4%), Cipla Ltd(6.51%), Apollo Hospitals Enterprise Ltd(5.79%), Dr Reddy's Laboratories Ltd(4.75%) as on March 2024
The alpha ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 1.65 | 2.21 | 4.22 |
As on March 2024
The alpha for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 0.94 | 0.95 | 0.92 |
As on March 2024
The Beta for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 2.95 | 0.96 | 0.99 |
As on March 2024
The sharpe ratio for Nippon India Pharma Fund - Direct Plan - Growth Plan is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund - Direct Plan - Growth Plan for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 14.24 | 15.52 | 18.6 |
As on March 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.76 as on March 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.83 as on March 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan, Kinjal Desai are the fund managers of Nippon India Pharma Fund - Direct Plan - Growth Plan
The Exit load of Nippon India Pharma Fund - Direct Plan - Growth Plan is 1%